Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

30
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
30
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

37
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
37
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

39
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
39
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

21
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
21
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

42
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
42

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

A cross-sectional analysis of county-level determinants of pandemic-era policy implementation.

Frontiers in public health·2026
Same author

Household Transmission of Enterovirus D68, Washington and Oregon, United States, 2022-2024.

Emerging infectious diseases·2026
Same author

Evaluating Associations Between Cumulative Use of Chronic Liver Injury-Inducing Antiretroviral Therapy and Hepatocellular Carcinoma, By Chronic Liver Disease Status.

Journal of acquired immune deficiency syndromes (1999)·2026
Same author

Evaluating the Association of a Self-Guided, Asynchronous, Balance Exercise Application on Fall-Related Injuries.

Journal of the American Geriatrics Society·2026
Same author

A call to action for the use of composite hematologic measurements in hereditary hemorrhagic telangiectasia and other chronic bleeding disorders.

Expert review of hematology·2026
Same author

Automated Health Care Messages and Unexpected Patient Responses.

JAMA network open·2026

Video Experimental Relacionado

Updated: Sep 1, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K

La asociación entre el COVID-19 y la gripe con el riesgo de eventos trombóticos arteriales y venosos entre los

Vincent Lo Re1,2, Sarah K Dutcher3, John G Connolly4

  • 1Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia.

JAMA
|August 16, 2022
PubMed
Resumen

La hospitalización con COVID-19 aumenta significativamente el riesgo de tromboembolismo venoso (coágulos de sangre), pero no el tromboembolismo arterial en comparación con la gripe. Este hallazgo es cierto tanto antes como durante la disponibilidad de la vacuna contra la COVID-19.

Más Videos Relacionados

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B
05:38

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Published on: January 30, 2017

15.8K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.6K

Videos de Experimentos Relacionados

Last Updated: Sep 1, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.3K
Rapid Molecular Detection and Differentiation of Influenza Viruses A and B
05:38

Rapid Molecular Detection and Differentiation of Influenza Viruses A and B

Published on: January 30, 2017

15.8K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.6K

Área de la Ciencia:

  • Vigilancia de la salud pública
  • Epidemiología
  • Enfermedades infecciosas

Sus antecedentes:

  • La incidencia precisa de tromboembolismo arterial y venoso en pacientes con COVID-19 no está bien establecida.
  • Comprender estos riesgos es crucial para la gestión de los pacientes y las estrategias de salud pública.

Objetivo del estudio:

  • Comparar el riesgo de 90 días de tromboembolismo arterial (ATE) y tromboembolismo venoso (VTE) en pacientes hospitalizados con COVID-19 frente a la gripe.
  • Evaluar estos riesgos en pacientes con COVID-19 antes y durante la disponibilidad de las vacunas contra la COVID-19.

Principales métodos:

  • Un estudio de cohorte retrospectivo utilizó datos del Sistema Sentinel de la FDA, incluidos más de 85,000 pacientes con COVID-19 y casi 8,300 pacientes con influenza.
  • Se utilizaron las puntuaciones de propensión y la regresión ponderada de Cox para ajustar las diferencias basales entre cohortes.
  • Los resultados incluyeron el diagnóstico hospitalario de ETA (infarto de miocardio, accidente cerebrovascular isquémico) y ETV (trombosis venosa profunda, embolia pulmonar) dentro de los 90 días.

Principales resultados:

  • La hospitalización con COVID-19 se asoció con un riesgo significativamente mayor de TEV en 90 días en comparación con la hospitalización por influenza (HRs ajustados de 1,60 y 1,89).
  • No se observó ninguna diferencia significativa en el riesgo de ETA de 90 días entre las hospitalizaciones por COVID-19 y la gripe (RH ajustados de 1,04 y 1,07).
  • La diferencia de riesgo absoluto de TEV fue notablemente mayor en pacientes con COVID-19, que osciló entre el 4,1% y el 5,5%.

Conclusiones:

  • La hospitalización por COVID-19, independientemente de la disponibilidad de la vacuna, está vinculada a un riesgo sustancialmente mayor de tromboembolismo venoso.
  • El riesgo de tromboembolismo arterial no parece ser significativamente elevado en pacientes con COVID-19 en comparación con pacientes con influenza.
  • Estos hallazgos subrayan la importancia de monitorear y administrar el riesgo de TEV en pacientes hospitalizados con COVID-19.